SEC Form 4 · accession 0001177648-18-000027
ENANTA PHARMACEUTICALS INC · ENTA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul J Mellett
Officer — Treasurer and CFO
Period of report
Jun 11, 2018
Accepted (ET)
Jun 12, 2018 · 5:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001177648
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 11, 2018 | S | 300 | $117.5233 | D | 88,158 | D | |
| Common StockF3 | Jun 11, 2018 | S | 2,600 | $119.3479 | D | 85,558 | D | |
| Common StockF4 | Jun 11, 2018 | S | 6,336 | $120.3686 | D | 79,222 | D | |
| Common StockF5 | Jun 11, 2018 | S | 5,153 | $121.4163 | D | 74,069 | D | |
| Common StockF6 | Jun 11, 2018 | S | 611 | $122.1733 | D | 73,458 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2018.
- F2The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $117.51 to $117.55, inclusive.
- F3The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $118.92 to $119.89, inclusive.
- F4The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $119.925 to $120.83, inclusive.
- F5The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $120.95 to $121.90, inclusive.
- F6The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $121.995 to $122.39, inclusive.
Remarks
The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 3, 4, 5 and 6 above.